Q1 2017 13F Holders as of 3/31/2017
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
112M
-
Number of holders
-
10
-
Total 13F shares, excl. options
-
770K
-
Shares change
-
+150K
-
Total reported value, excl. options
-
$1.12M
-
Value change
-
+$227K
-
Number of buys
-
6
-
Number of sells
-
-1
-
Price
-
$1.46
Significant Holders of Viking Therapeutics, Inc. - COMMON STOCK (VKTX) as of Q1 2017
11 filings reported holding VKTX - Viking Therapeutics, Inc. - COMMON STOCK as of Q1 2017.
Viking Therapeutics, Inc. - COMMON STOCK (VKTX) has 10 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 770K shares
of 112M outstanding shares and own 0.69% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (331K shares), RENAISSANCE TECHNOLOGIES LLC (266K shares), GRT CAPITAL PARTNERS L.L.C. (104K shares), GEODE CAPITAL MANAGEMENT, LLC (31.3K shares), NORTHERN TRUST CORP (17K shares), Acrospire Investment Management LLC (12.6K shares), UBS Group AG (4.51K shares), MANUFACTURERS LIFE INSURANCE COMPANY, THE (1.81K shares), REILLY FINANCIAL ADVISORS, LLC (1.25K shares), and BlackRock Inc. (703 shares).
This table shows the top 10 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.